Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II) - PubMed (original) (raw)
. 1991 Nov 15;147(10):3459-65.
Affiliations
- PMID: 1834741
Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II)
D Harrison et al. J Immunol. 1991.
Abstract
Two genes encode the CD16 low affinity IgG FcR. CD16-I (Fc gamma RIII-1) is expressed on PMN as a phosphatidylinositol-glycan anchored glycoprotein. CD16-II (Fc gamma RIII-2) is expressed on NK cells and macrophages as a transmembrane glycoprotein associated with CD3 zeta or Fc epsilon RI-gamma. NK cells spontaneously release soluble CD16-II from the cell surface and this is enhanced by activation with phorbol ester. In this study, we demonstrate that a metalloprotease is involved in the spontaneous and PMA-induced release of CD16-II from NK cells. 1,10-phenanthroline, an inhibitor of Zn(2+)-dependent metalloproteases, efficiently inhibits CD16-II release. 1,7-phenanthroline, an inactive analogue that doesn't chelate Zn2+ or other divalent metal cations, and inhibitors of serine proteases do not affect spontaneous or PMA-induced release of CD16-II. Murine P815 mastocytoma cells transfected with human CD16-II cDNA shed membrane CD16, and 1,10-phenanthroline inhibits this process. P815 transfectants expressing CD16-II molecules with truncated cytoplasmic domains also release soluble receptors, indicating that the cytoplasmic segment of CD16-II is not required for interaction with the protease or the cytoskeleton. By contrast, 1,10-phenanthroline does not inhibit PMA-induced release of CD16-I glycoprotein from PMN, indicating a different mechanism of release for this phosphatidylinositol-glycan anchored molecule. Prior studies have demonstrated that NK cells are activated via the inositol phosphate pathway after engagement of CD16-II by immune complexes or Ig-coated tumor cell targets. A membrane metalloprotease with substrate specificity for CD16-II that is activated by PKC stimulation may provide a mechanism for releasing the immune complex or target from the effector cells and halting signal transduction.
Similar articles
- Platelet-induced expression of Fc gamma RIII (CD16) on human monocytes.
Phillips JH, Chang CW, Lanier LL. Phillips JH, et al. Eur J Immunol. 1991 Apr;21(4):895-9. doi: 10.1002/eji.1830210406. Eur J Immunol. 1991. PMID: 1826887 - Receptors for the Fc fragment of IgG on natural killer cells.
Trinchieri G, Valiante N. Trinchieri G, et al. Nat Immun. 1993 Jul-Oct;12(4-5):218-34. Nat Immun. 1993. PMID: 8257828 Review. - Structure and function of the CD16:zeta:gamma complex expressed on human natural-killer cells.
Vivier E, Ackerly M, Rochet N, Anderson P. Vivier E, et al. Int J Cancer Suppl. 1992;7:11-4. Int J Cancer Suppl. 1992. PMID: 1428397 Review.
Cited by
- Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges.
Wu J. Wu J. BioDrugs. 2024 Jul;38(4):499-509. doi: 10.1007/s40259-024-00657-2. Epub 2024 May 3. BioDrugs. 2024. PMID: 38700835 Free PMC article. Review. - Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM, Farley LE, Harris RM, Judge SJ, Lammers M, Iranpur KR, Johnson EG, Dunai C, Murphy WJ, Brown CT, Rebhun RB, Kent MS, Canter RJ. Razmara AM, et al. J Immunother Cancer. 2024 Apr 16;12(4):e007963. doi: 10.1136/jitc-2023-007963. J Immunother Cancer. 2024. PMID: 38631708 Free PMC article. - Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F, Esmaeil N, Abbaspour M. Ghaedrahmati F, et al. Cancer Commun (Lond). 2023 Feb;43(2):177-213. doi: 10.1002/cac2.12394. Epub 2022 Dec 30. Cancer Commun (Lond). 2023. PMID: 36585761 Free PMC article. Review. - Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.
Medjouel Khlifi H, Guia S, Vivier E, Narni-Mancinelli E. Medjouel Khlifi H, et al. Front Immunol. 2022 Jun 10;13:898745. doi: 10.3389/fimmu.2022.898745. eCollection 2022. Front Immunol. 2022. PMID: 35757695 Free PMC article. Review. - Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F, Fredericks N, Snowden A, Allegrezza MJ, Moreno-Nieves UY. Rossi F, et al. Front Immunol. 2022 Jun 2;13:886429. doi: 10.3389/fimmu.2022.886429. eCollection 2022. Front Immunol. 2022. PMID: 35720306 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources